Deutsche Bank assumed coverage on shares of Centene (NYSE:CNC) in a research note published on Thursday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $62.00 target price on the stock.

CNC has been the subject of a number of other reports. ValuEngine cut Centene from a sell rating to a strong sell rating in a report on Tuesday, July 2nd. Morgan Stanley cut their price objective on Centene from $71.00 to $64.00 and set an overweight rating for the company in a report on Friday, August 23rd. Finally, Zacks Investment Research cut Centene from a buy rating to a hold rating and set a $49.00 target price for the company. in a report on Monday, September 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $73.10.

CNC opened at $45.40 on Thursday. The stock has a 50-day moving average price of $48.21 and a 200-day moving average price of $53.14. Centene has a 12-month low of $44.50 and a 12-month high of $74.49. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $18.57 billion, a P/E ratio of 12.82, a PEG ratio of 0.72 and a beta of 0.85.

Centene (NYSE:CNC) last posted its quarterly earnings data on Tuesday, July 23rd. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.10. Centene had a return on equity of 15.87% and a net margin of 1.84%. The firm had revenue of $18.36 billion during the quarter, compared to analysts’ expectations of $18.02 billion. During the same period in the prior year, the business earned $0.90 EPS. The company’s revenue for the quarter was up 29.4% compared to the same quarter last year. On average, equities research analysts predict that Centene will post 4.42 EPS for the current year.

In other Centene news, Director Jessica L. Blume purchased 2,850 shares of the stock in a transaction on Friday, July 26th. The stock was acquired at an average price of $52.99 per share, with a total value of $151,021.50. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 2.50% of the company’s stock.

Several large investors have recently made changes to their positions in CNC. Compagnie Lombard Odier SCmA bought a new position in shares of Centene in the 2nd quarter worth approximately $30,000. Zions Bancorporation N.A. raised its position in shares of Centene by 131.5% in the 1st quarter. Zions Bancorporation N.A. now owns 602 shares of the company’s stock worth $32,000 after acquiring an additional 342 shares in the last quarter. Global Retirement Partners LLC raised its position in shares of Centene by 568.0% in the 1st quarter. Global Retirement Partners LLC now owns 648 shares of the company’s stock worth $34,000 after acquiring an additional 551 shares in the last quarter. Reilly Financial Advisors LLC raised its position in shares of Centene by 133.3% in the 2nd quarter. Reilly Financial Advisors LLC now owns 700 shares of the company’s stock worth $37,000 after acquiring an additional 400 shares in the last quarter. Finally, Berman Capital Advisors LLC increased its position in Centene by 369.3% during the 1st quarter. Berman Capital Advisors LLC now owns 826 shares of the company’s stock valued at $43,000 after buying an additional 650 shares in the last quarter. 97.07% of the stock is owned by hedge funds and other institutional investors.

Centene Company Profile

Centene Corporation operates as a diversified and multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. The company's Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which covers dually eligible individuals, as well as aged, blind, or disabled programs.

Recommended Story: Buy-Side Analysts

Analyst Recommendations for Centene (NYSE:CNC)

Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.